ES2539405T3 - Vendaje para heridas biorresorbible - Google Patents
Vendaje para heridas biorresorbible Download PDFInfo
- Publication number
- ES2539405T3 ES2539405T3 ES12729582.2T ES12729582T ES2539405T3 ES 2539405 T3 ES2539405 T3 ES 2539405T3 ES 12729582 T ES12729582 T ES 12729582T ES 2539405 T3 ES2539405 T3 ES 2539405T3
- Authority
- ES
- Spain
- Prior art keywords
- fibers
- acid
- wound dressing
- gdf
- bioresorbable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/62—Compostable, hydrosoluble or hydrodegradable materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/04—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres having existing or potential cohesive properties, e.g. natural fibres, prestretched or fibrillated artificial fibres
- D04H1/30—Collagen
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4266—Natural fibres not provided for in group D04H1/425
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Surgery (AREA)
Abstract
Un tejido no tejido que comprende: fibras de una materia prima fibrosa que comprende polímeros biorresorbibles y/o biocompatibles, incluyendo las fibras al menos una sustancia biológicamente activa, que está distribuida en las fibras, en las que la sustancia biológicamente activa es una proteína relacionada con GDF-5, que es una proteína que comprende un dominio de nudo de cistina con una identidad de aminoácidos de al menos 60% con el dominio de nudo de cistina de 102 aa de GDF-5 humana según los aminoácidos 400-501 de SEC ID NO:2.
Description
5
15
25
35
45
E12729582
11-06-2015
unión dermoepitelial (Fitzpatrick y Rosen, J. Cosmet. Laser Ther, 5: 25-34 (2003)). Un cóctel (TNS Recovery Complex, SkinMedica, Inc. Carlsbad, CA, USA) que contiene siete citocinas (VEGF, IL-6 y -8, HGF, PDGF-a, GCSF, y TGF-1) derivadas de fibroblastos de prepucio neonatal se ensayó en un estudio multicéntrico. La evaluación mostró mejora en la textura de la piel, y menor número de arrugas (Rokhsar, C.K. et al., Dermatol. Surg. 31: 11661178 (2005)). El factor de crecimiento epidérmico recombinante (ReVive Skincare) y el factor de crecimiento vegetal N-furfuriladenina (quinetina) también están en el mercado. Todas estas proteínas se pueden usar junto con las proteínas relacionadas con GDF-5 de la invención. Otras proteínas que actúan sinérgicamente si se combinan con proteínas relacionadas con GDF-5 se describen en la bibliografía/patentes, por ejemplo en el documento WO 99/15191. Se prefieren neurotrofinas, proteínas hedgehog y proteínas de la familia del factor de crecimiento transformante, incluyendo, pero sin limitarse a, TGF-alfas, TGF-betas, activinas, BMPs y GDFs. Se prefiere especialmente una combinación con una cualquiera de EGF, TGF-1, TGF-2, TGF-3, NGF y/o GDNF.
Otros componentes aceptables en los tejidos son:
-Retinoides (derivados de vitamina A) que conservan la integridad de las superficies mucosales/epiteliales;
-Hidroxiácidos (ácidos carboxílicos orgánicos clasificados además en alfa-hidroxiácidos (AHA) y betahidroxiácidos (BHA)) que potencian el desprendimiento epidérmico, es decir, ácido glicólico, ácido láctico, ácido cítrico, ácido mandélico, ácido málico, y ácido tartárico;
-Antioxidantes que contrarrestan los efectos dañinos de radicales libres, es decir, vitamina C, vitamina E, pantenol, ácido lipoico, ubiquinona, niacinamida, dimetilaminoetanol, trampas de espín, melatonina, catalasa, glutationa, superóxido dismutasa, peroxidasa, glucopiranósidos, polifenoles, cisteína, alantoína, furfuriladenina, ácido úrico, y carnosina;
-Agentes despigmentantes que alivian la hiperpigmentación, es decir, N-acetil-4-S-cisteanimilfenol, ácido kójico, arbutina, ácido azaleico, compuesto de la morera del papel, agentes exfoliantes químicos (resorcinol, ácido salicílico), fórmula de Kligman, fórmula de Pathak, y fórmula de Westerhofs;
-Sustancias botánicas, es decir, camomila, ginseng, gingko biloba, curcumina, glicirricina, capsaicina, y aloe vera;
-Glucosaminoglicanos que apoyan la regeneración epidérmica, es decir, ácido hialurónico;
-Anticelulíticos que median la lipolisis, es decir, estimulantes beta-adrenérgicos tales como teobromina, teofilina, aminofilina, cafeína, epinefrina, y estimulantes alfa1-adrenérgicos tales como yohimbina, piperoxano, y fentolamina;
-Hormonas, es decir, estrógenos, progesterona, testosterona, y hormona del crecimiento;
-Agentes antimicrobianos, es decir, triclosán, clorhexidina, povidona yodada, peróxido de hidrógeno, preparaciones anticaspa, cinc piritiona;
-Filtros químicos de la radiación UV, es decir, 3-benciliden alcanfor (3-BC) o 4-metilbenciliden alcanfor (4-MBC);
-Además, tampones, estabilizantes, conservantes, agentes reductores, agentes quelantes antioxidantes, agentes que modifican la isotonicidad, desodorantes, anestésicos, adyuvantes, y aditivos que potencian la solubilidad.
Estos son solamente ejemplos no limitantes de posibles aditivos, y un trabajador experto en la técnica puede añadir fácilmente otros excipientes que están actualmente en uso que son considerados generalmente como seguros. Para más información sobre métodos para formular una composición farmacéutica y la selección de sustancias farmacéuticamente aceptables, por favor véanse, por ejemplo, Remington’s Pharmaceutical Sciences (luth ed.; Mack Publishing Company, Eaton, Pennsylvania, 1990), Wang et al. (1980), J. Parent. Drug Assn. 34 (6): 452-462 (1980); Wang et al. (1988), J. Parent. Sci. and Tech. 42: 4-26; Lachman et al. (1968), Drug and Cosmetic Industry 102(1): 36-38, 40 y 146-148; y Akers (1988)J. Parent. Sci. and Tech. 36 (5): 222-228.
Preferiblemente se eluye entre 1% y 100% de la sustancia biológicamente activa desde el tejido no tejido durante 3 a 7 días en contacto con fluidos corporales, plasma, medios o disolución tampón. Lo más preferible, se libera entre 10% y 100% de la sustancia bioactiva en condiciones fisiológicas (tampón PBS, suero fetal de ternera al 10%, 37ºC).
Las siguientes figuras, ejemplos y protocolos de secuencias están destinadas a ilustrar adicionalmente la invención.
SEC ID NO: 1 muestra la secuencia de ADN, y SEC ID NO: 2 muestra la secuencia proteica del precursor de GDF-5 humana.
SEC ID NO: 3 muestra la secuencia de ADN, y SEC ID NO: 4 muestra la secuencia proteica de la GDF-5 monómera madura humana.
8
Claims (1)
-
imagen1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11170971 | 2011-06-22 | ||
EP11170971A EP2537538A1 (en) | 2011-06-22 | 2011-06-22 | Bioresorbable Wound Dressing |
PCT/EP2012/061965 WO2012175611A1 (en) | 2011-06-22 | 2012-06-21 | Bioresorbable wound dressing |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2539405T3 true ES2539405T3 (es) | 2015-06-30 |
Family
ID=46354320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12729582.2T Active ES2539405T3 (es) | 2011-06-22 | 2012-06-21 | Vendaje para heridas biorresorbible |
Country Status (13)
Country | Link |
---|---|
US (3) | US9278156B2 (es) |
EP (2) | EP2537538A1 (es) |
JP (1) | JP6138773B2 (es) |
KR (1) | KR101964482B1 (es) |
CN (1) | CN103874516B (es) |
AU (1) | AU2012274046C1 (es) |
BR (1) | BR112013032714A2 (es) |
CA (1) | CA2839142C (es) |
ES (1) | ES2539405T3 (es) |
RU (1) | RU2577155C2 (es) |
TW (1) | TWI572336B (es) |
WO (1) | WO2012175611A1 (es) |
ZA (1) | ZA201309341B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999702B2 (en) * | 2010-04-09 | 2018-06-19 | Kci Licensing Inc. | Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds |
EP2537538A1 (en) | 2011-06-22 | 2012-12-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Bioresorbable Wound Dressing |
US11173227B2 (en) | 2013-05-22 | 2021-11-16 | The Penn State Research Foundation | Wound dressings and applications thereof |
DK3427726T3 (da) * | 2016-03-07 | 2023-05-15 | Univ Osaka | Ark med vedvarende lægemiddelfrigvelse til behandling af nerveskade |
FR3058041B1 (fr) | 2016-10-28 | 2021-06-04 | Centre Hospitalier Regional Univ Lille | Dispositif apte a etre implante dans le corps d'un sujet pour former un implant - masse tissulaire et procede associes. |
AU2018266546B2 (en) | 2017-05-07 | 2024-06-13 | Locus Ip Company, Llc | Cosmetic compositions for skin health and methods of using same |
EP3703633B2 (en) | 2017-11-03 | 2024-06-26 | 3M Innovative Properties Company | Extended wear-time dressing |
CN108210979B (zh) * | 2018-01-28 | 2020-09-29 | 山东东贝医药科技有限公司 | 一种医用杀菌纤维敷料 |
CN108286132B (zh) * | 2018-03-27 | 2020-06-23 | 界首市圣通无纺布有限公司 | 一种具有抗菌功能的易降解无纺布加工方法 |
CA3107300A1 (en) | 2018-05-25 | 2019-11-28 | Locus Ip Company, Llc | Therapeutic compositions for enhanced healing of wounds and scars |
CN108893792B (zh) * | 2018-07-13 | 2020-11-03 | 深圳大学 | 生物活性纤维及其制备方法、应用和制备系统 |
BR112021024419A2 (pt) * | 2019-06-03 | 2022-01-18 | Convatec Ltd | Métodos e dispositivos para desfazer e confinar patógenos |
US20220409769A1 (en) * | 2019-09-17 | 2022-12-29 | Mayo Foundation For Medical Education And Research | Methods and materials for treating fistulas |
WO2022138206A1 (ja) * | 2020-12-22 | 2022-06-30 | 日本毛織株式会社 | 創傷被覆材 |
US20240091404A1 (en) * | 2021-02-09 | 2024-03-21 | Shin-Etsu Chemical Co., Ltd. | Gelatin-containing device |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19525416A1 (de) | 1995-07-12 | 1997-01-16 | Bioph Biotech Entw Pharm Gmbh | Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems |
JP3193050B2 (ja) | 1992-02-12 | 2001-07-30 | ビオファルム ゲゼルシャフト ツア ビオテヒノロ ギッシェン エントヴィックルング フォン ファル マカ ミット ベシュレンクテル ハフツング | 新規の増殖/分化因子をコード化するdna配列 |
WO1994015949A1 (en) | 1993-01-12 | 1994-07-21 | Johns Hopkins University School Of Medicine | Growth differentiation factor-5 |
IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
ES2255059T3 (es) | 1993-12-07 | 2006-06-16 | Genetics Institute, Llc | Bmp-12, bmp-13 y composiciones suyas inductoras de tendon. |
AU1120295A (en) | 1994-11-07 | 1996-05-31 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Cartilage-derived morphogenetic proteins |
JPH08209435A (ja) * | 1995-01-30 | 1996-08-13 | Sangi Co Ltd | 生体適合糸 |
PL186518B1 (pl) | 1995-04-19 | 2004-01-30 | Bioph Biotech Entw Pharm Gmbh | Białko, kompozycja farmaceutyczna i sposób wytwarzania białka |
PT831884E (pt) | 1995-06-05 | 2003-11-28 | New York Society | Uso de proteinas morfogeneticas do caso para cicatrizacao e reparacao da ligacao do tecido conjuntivo |
JPH0931098A (ja) | 1995-07-24 | 1997-02-04 | Hoechst Japan Ltd | 新規なタンパク質hmwヒトmp52 |
ZA966489B (en) | 1995-08-03 | 1997-02-26 | Bioph Biotech Entw Pharm Gmbh | New protein human MP52 Arg. |
DE19647853A1 (de) * | 1996-11-19 | 1998-05-20 | Bioph Biotech Entw Pharm Gmbh | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität |
JPH11335398A (ja) | 1998-05-22 | 1999-12-07 | Hoechst Marion Roussel Kk | 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬 |
EP1074620A1 (en) | 1999-08-06 | 2001-02-07 | HyGene AG | Monomeric protein of the TGF-beta family |
CA2301693A1 (en) | 1997-09-19 | 1999-04-01 | Klaus Unsicker | Cytokines having neurotrophic activity |
US6992066B2 (en) * | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
US7020845B1 (en) * | 1999-11-15 | 2006-03-28 | Gottfurcht Elliot A | Navigating internet content on a television using a simplified interface and a remote control |
EP1372698A2 (en) | 2001-03-23 | 2004-01-02 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders |
WO2004000915A2 (en) * | 2002-06-24 | 2003-12-31 | Tufts University | Silk biomaterials and methods of use thereof |
TW200410714A (en) | 2002-08-07 | 2004-07-01 | Smithkline Beecham Corp | Electrospun amorphous pharmaceutical compositions |
EP1462126A1 (en) | 2003-03-28 | 2004-09-29 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Improved Osteoinductive Materials |
JP2005005144A (ja) * | 2003-06-12 | 2005-01-06 | Nemoto:Kk | スイッチカバー |
US7704740B2 (en) * | 2003-11-05 | 2010-04-27 | Michigan State University | Nanofibrillar structure and applications including cell and tissue culture |
JP4618997B2 (ja) * | 2003-12-09 | 2011-01-26 | テルモ株式会社 | ステントおよびその製造方法 |
US8221780B2 (en) * | 2004-04-20 | 2012-07-17 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
EP1698691A1 (en) * | 2005-03-04 | 2006-09-06 | Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH | Growth factor mutants with improved biological activity |
JP2006254722A (ja) * | 2005-03-15 | 2006-09-28 | Toray Ind Inc | 細胞足場材料 |
DE102005048939A1 (de) | 2005-07-01 | 2007-01-11 | Carl Freudenberg Kg | Vorrichtung, Anordnung und Verfahren zur Herstellung von Fasern und eine solche Fasern umfassende Anordnung |
US20100303881A1 (en) | 2006-02-02 | 2010-12-02 | The John Hopkins University | Therapeutic Electrospun Fiber Compositions |
EP1880731A1 (en) | 2006-07-18 | 2008-01-23 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Human growth and differentiation factor GDF-5 |
WO2008093341A2 (en) * | 2007-01-31 | 2008-08-07 | Technion Research & Development Foundation Ltd. | Electrospun scaffolds and methods of generating and using same |
DE102007011606A1 (de) * | 2007-03-02 | 2008-09-04 | Carl Freudenberg Kg | Faser-Wirrgelege |
KR101538981B1 (ko) | 2007-09-13 | 2015-07-23 | 드레징 인터내셔널 엔. 브이. | 준설을 최적화하기 위한 시스템 및 방법 |
DE102007044648B4 (de) * | 2007-09-18 | 2020-11-26 | Carl Freudenberg Kg | Bioresorbierbarer Gelatinevliesstoff |
US20090163936A1 (en) | 2007-12-21 | 2009-06-25 | Chunlin Yang | Coated Tissue Engineering Scaffold |
US20100002151A1 (en) * | 2008-07-01 | 2010-01-07 | Yang Pan | Handheld media and communication device with a detachable projector |
US7644955B1 (en) * | 2008-07-03 | 2010-01-12 | Naris Komolrochanaporn | Quick coupling type fitting |
US8557271B2 (en) * | 2008-07-16 | 2013-10-15 | Warsaw Orthopedic, Inc. | Drug depot implantable within a joint |
TWM370392U (en) * | 2009-06-19 | 2009-12-11 | zhi-sheng Chen | Curative ventilating dressing |
EP2598177B1 (en) * | 2010-07-30 | 2015-06-17 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Drug delivery devices and growth factor formulations for accelerated wound healing |
EP2537538A1 (en) | 2011-06-22 | 2012-12-26 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH | Bioresorbable Wound Dressing |
-
2011
- 2011-06-22 EP EP11170971A patent/EP2537538A1/en not_active Ceased
-
2012
- 2012-06-21 TW TW101122140A patent/TWI572336B/zh not_active IP Right Cessation
- 2012-06-21 KR KR1020147001041A patent/KR101964482B1/ko active IP Right Grant
- 2012-06-21 EP EP12729582.2A patent/EP2723408B1/en not_active Not-in-force
- 2012-06-21 JP JP2014516347A patent/JP6138773B2/ja not_active Expired - Fee Related
- 2012-06-21 WO PCT/EP2012/061965 patent/WO2012175611A1/en active Application Filing
- 2012-06-21 CN CN201280037651.7A patent/CN103874516B/zh not_active Expired - Fee Related
- 2012-06-21 AU AU2012274046A patent/AU2012274046C1/en not_active Ceased
- 2012-06-21 CA CA2839142A patent/CA2839142C/en not_active Expired - Fee Related
- 2012-06-21 ES ES12729582.2T patent/ES2539405T3/es active Active
- 2012-06-21 BR BR112013032714A patent/BR112013032714A2/pt not_active Application Discontinuation
- 2012-06-21 RU RU2014101762/15A patent/RU2577155C2/ru not_active IP Right Cessation
- 2012-06-21 US US14/128,185 patent/US9278156B2/en not_active Expired - Fee Related
-
2013
- 2013-12-10 ZA ZA2013/09341A patent/ZA201309341B/en unknown
-
2016
- 2016-01-15 US US14/996,483 patent/US9782511B2/en not_active Expired - Fee Related
-
2017
- 2017-09-06 US US15/696,321 patent/US20180008743A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9782511B2 (en) | 2017-10-10 |
AU2012274046B2 (en) | 2016-02-18 |
CN103874516A (zh) | 2014-06-18 |
BR112013032714A2 (pt) | 2017-01-24 |
US20180008743A1 (en) | 2018-01-11 |
ZA201309341B (en) | 2015-11-25 |
KR101964482B1 (ko) | 2019-04-01 |
CA2839142C (en) | 2019-04-16 |
KR20140146035A (ko) | 2014-12-24 |
CA2839142A1 (en) | 2012-12-27 |
TWI572336B (zh) | 2017-03-01 |
WO2012175611A1 (en) | 2012-12-27 |
US20160199530A1 (en) | 2016-07-14 |
RU2014101762A (ru) | 2015-07-27 |
AU2012274046C1 (en) | 2016-07-14 |
EP2537538A1 (en) | 2012-12-26 |
CN103874516B (zh) | 2016-06-01 |
TW201302170A (zh) | 2013-01-16 |
US9278156B2 (en) | 2016-03-08 |
AU2012274046A1 (en) | 2014-01-23 |
JP6138773B2 (ja) | 2017-05-31 |
US20140141050A1 (en) | 2014-05-22 |
RU2577155C2 (ru) | 2016-03-10 |
EP2723408B1 (en) | 2015-04-15 |
EP2723408A1 (en) | 2014-04-30 |
JP2014522918A (ja) | 2014-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2539405T3 (es) | Vendaje para heridas biorresorbible | |
Mohanty et al. | A human epidermal growth factor-curcumin bandage bioconjugate loaded with mesenchymal stem cell for in vivo diabetic wound healing | |
BR112013020005A2 (pt) | peptídeo de fórmula geral r1-wn-xm-aa1-aa2-aa3-aa4-aa5-aa6-yp-zq-r2, seus estereoisômeros, misturas dos mesmos e/ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica | |
BRPI0913831B8 (pt) | peptídeo com a fórmula geral (i), seus estereoisômeros, suas misturas, ou seus sais cosmética ou farmaceuticamente aceitáveis, processo para a preparação de um peptídeo com a fórmula geral (i), seus estereoisômeros, suas misturas, ou seus sais cosmética ou farmaceuticamente aceitáveis e composição cosmética ou farmacêutica | |
Ookubo et al. | The transdermal inhibition of melanogenesis by a cell-membrane-permeable peptide delivery system based on poly-arginine | |
KR102359387B1 (ko) | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 | |
US9815878B2 (en) | Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging | |
MX2011008616A (es) | Peptidos utiles en el tratamiento y/o cuidado de la piel , mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. | |
WO2017164609A3 (ko) | 피부 재생 또는 상처 치료용 펩타이드 및 이의 용도 | |
KR101592864B1 (ko) | 상처 치료 또는 상처 치료 촉진용 약학 조성물 | |
US20220079990A1 (en) | Methods and compositions for treating skin and hair disorders | |
JP2016501866A5 (es) | ||
CN108992384A (zh) | 一种治疗黄褐斑的敷料 | |
EA201590546A1 (ru) | Способы лечения заболеваний, связанных с волосами | |
JP2015528479A5 (es) | ||
MX336278B (es) | Composiciones y metodos para la prevencion y el tratamiento de heridas. | |
ES2887588T3 (es) | Composiciones derivadas de pasta de fracción de Cohn y uso de las mismas | |
Li et al. | Umbilical cord‐derived mesenchymal stem cell secretome promotes skin regeneration and rejuvenation: From mechanism to therapeutics | |
KR20220011861A (ko) | 줄기세포 유래의 엑소좀 또는 이의 동결건조제제를 유효성분으로 포함하는 항암제나 방사선 조사로 인한 피부특이반응의 예방, 억제, 완화, 개선 또는 치료용 조성물 | |
CN105055187B (zh) | 一种面部年轻化美容制剂及其制备方法 | |
CN118043341A (zh) | 具有抗老化活性的肽及其用途 | |
KR102209294B1 (ko) | 줄기세포 유래 엑소좀의 동결건조제제 및 이를 유효성분으로 포함하는 발모 촉진 또는 탈모 방지용 조성물 | |
EA201591095A1 (ru) | Белок slurp-1 для применения в лечении глазных болезней | |
JP2015537028A5 (es) | ||
RU2018146294A (ru) | Композиция для лечения уремического зуда |